Search

AbbVie announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg [...]

'We continue to analyze the data from our two Phase 2 trials of zelnecirnon in atopic dermatitis and asthma, which we closed prior to completing enrollment following the clinical holds [...]

AbbVie announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ, [...]

Connect Biopharma announced that post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis showed that CBP-201 led to rapid and sustained improvement in AD [...]

Aslan Pharmaceuticals announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology - EADV - annual congress in Milan. Three posters are being presented [...]

AbbVie announced new analyses from the Phase 3 Rinvoq - upadacitinib - atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology Virtual [...]

New analyses from Dupixent trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated [...]

Eli Lilly (LLY) and Incyte (INCY) announced that the FDA has extended the review period for the supplemental new drug application, or sNDA, for baricitinib for the treatment of adults [...]

AbbVie announced new results from the ongoing Phase 2b study including longer-term efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult [...]

XBiotech announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis, or AD. In the first phase of the study, nine patients received [...]